Positive interim data for Immunotherapeutics' MIS416 in chronic progressive MS
This article was originally published in Scrip
Executive Summary
Innate Immunotherapeutics, based in Auckland, New Zealand, said that its lead compound, MIS416 – from its proprietary immune modulating microparticle technology - showed positive Phase I/II interim data, as the preliminary data indicate it was safe and well tolerated. The trial was designed to review the effect of weekly intravenously administered doses in patients with secondary progressive multiple sclerosis.